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SHORT COMMUNICATION
Oral contraceptives and survival in breast cancer
F.C. Millardl*, J.M. Bliss2, C.E.D. Chilvers2 & J.-C. Gazet1
ISt. George's'Hospital, Blackshaw Road, London SWJ 7 and 2Section ofEpidemiology, Institute of Cancer Research, Block D,
Clifton Avenu-e, Sutton, Surrey, UK.
It has been suggested that women with breast cancer and a
history of oral contraceptive (OC) use survive significantly
longer than breast cancer patients who have not used OCs
(Matthews et al., 1981; Spencer et al., 1978). However
Rosner & Lane (1986) and Vessey et al. (1979) found no
evidence of such an effect. We have used data recorded
routinely for all breast cancer patients attending a single
clinic to investigate these contradictory results further.
A retrospective review of clinical notes of patients treated
by one of us (J-CG) at the Royal Marsden Hospital between
1967 and 1984 was carried out. Women born before 1930
were excluded as they would be unlikely to have used oral
contraceptives, and private patients resident abroad were
excluded as data were incomplete. Details of age at
diagnosis, parity, age at menarche, weight, age at 1st full
term pregnancy, past history of benign breast disease and
family history of breast cancer in 1st degree relatives were
abstracted. Information on use of oral contraceptives was
usually collected on the standard history sheet; on this sheet
'users' were defined as those taking OCs for 6 months or
more. Where this item was not completed, the clinical notes
at presentation were searched for this information using the
same definition of use as that on the standard history sheet.
We took care to exclude all patients (<10%) whose clinical
notes at presentation did not contain a positive statement on
use or non-use of OCs. Clinical TNM staging was available
for all patients and oestrogen receptor status was abstracted
where available. Dates of first distant recurrence and death
(or date last seen) were recorded. A comparison of
metastatis free survival and overall survival in OC users and
non-users was performed using the logrank test (Peto et al.,
1977), and the relative risk of death was determined using
Cox regression methods (Cox & Oakes, 1984).
A definitive history of use or non-use of OCs had been
recorded for 296 patients. Of these, 14 patients were
recorded as having bilateral primaries (5.5% (6/109) of OC
users and 4.3% (8/187) of non-users), 14 had metastatic
disease on admission (5.5% of OC users and 4.3% of non-
users) and 5 had intra-duct carcinomas; these patients were
excluded from the main analyses leaving a total of 263 cases.
Ninety-four patients (36%) had used OCs for more than 6
months.
The OC users were younger at diagnosis than the non-
users (40.5 years compared to 43.7 years, see Table I). This
is reflected in the higher proportion of premenopausal
women in the OC-user group (86%) compared to the non-
user group (75%). The two groups were similar with respect
to the major risk factors for breast cancer (age at menarche,
age at first full-term pregnancy, and family history of breast
cancer) and the major prognostic factors at presentation
(clinical T and N stage and oestrogen receptor status, see
Table I). No evidence was found of a difference between OC
users and non-users in metastasis free survival (OC users
Obs =30 Exp =27.7; Non-users Obs = 53 Exp =55.3,
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Table I Characteristics of users and non-users of oral contraceptives
Users Non-users
Mean age (range) 40.5 yrs (24,52) 43.7 yrs (24, 53)
Premenopausal 81/94 (86%) 127/169 (75%)
Clinical T Stage: Tl +T2 73/94 (78%) 134/169 (79%)
Clinical N Stage: NO 57/94 (61%) 103/169 (61%)
Oestrogen receptor positivea 25/38 (66%) 43/64 (67%)
History of benign breast
disease 14/94 (15%) 32/168 (19%)
Family history of breast
cancer 6/94 (6%) 14/164 (9%)
a> 15 fmolmg-1 cytosol protein.
Logrank statistic=0.17 P=0.68, Figure 1) or overall survival
(OC users Obs=24 Exp= 19.7; Non-users Obs=35
Exp=39.3, Logrank statistic= 1.08 P=0.30). Stratification
for menopausal status and clinical stage did not affect this
finding. The relative risk of death for OC users compared to
non-users was 1.36 with 95% Confidence Interval (0.81,
2.29); after adjusting for clinical stage and age at diagnosis
the relative risk remains unchanged.
An apparent improvement in survival in breast cancer
patients with a history of OC use has been reported in four
studies (Rosner & Lane, 1986; Matthews et al., 1981; Vessey
et al., 1979; Spencer et al., 1978). In two of these studies
(Rosner & Lane, 1986; Vessey et al., 1979), however, this
beneficial effect was explained by earlier stage at diagnosis
and disappeared when stage of disease at presentation was
allowed for in the analysis. Matthews et al. (1981) and
Spencer et al. (1978) still found a residual beneficial effect, at
least in subgroups of the patients studied. Matthews et al.
(1981) report comparisons of recurrence and survival in
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those patients treated by radical mastectomy. This group (65
OC users and 62 non-users) is probably similar in character-
istics to those studied here since their total group included
patients presenting with intraduct tumours and with
metastatic disease which we specifically excluded from
analysis. The OC users survived significantly longer than the
non-users. Spencer et al. (1978) report their results separately
for patients with pathological grade I and grade II tumours.
The recurrence rate was significantly higher in OC non-users
than in OC users among those patients with grade II
tumours. The combined results for patients with grade I and
grade II tumours with suitable allowance for tumour grade
are not given in their paper and the sub-group analysis
should be interpreted with caution.
One clear difference between our study and these two
earlier reports lies in our failure to find any difference in the
proportion of familial breast cancers among the OC users
and non-users; both Matthews et al. (1981) and Spencer et
al. (1978) found significantly more women to have a family
history of breast cancer in their OC-user groups. Matthews
et al. (1981) suggested that 'familial' tumours might be less
aggressive and hence the survival advantage. All four of
these studies (Rosner & Lane, 1986; Matthews et al., 1981;
Vessey et al., 1979; Spencer et al., 1978) find evidence that
women with breast cancer who have used OCs present with
earlier stage disease than non-users but the Royal College of
General Practitioners (1981) found the opposite. Vessey et al.
(1979) examined the question of surveillance bias (OC users
being more likely to have frequent breast examination by a
doctor than non-users) in detail. They found that although
OC users did have more frequent breast examination than
non-users, 85% of tumours in both the user and non-user
groups were found by the woman herself or her husband.
They concluded that the earlier TNM stage was unlikely to
be due to surveillance bias but could be due to a beneficial
effect of OCs on tumour growth or spread. In our data,
stage at presentation and survival are independent of OC
use. Moreover we found the proportion of OC users and
non-users with a family history of breast cancer to be
similar.
In common with other case series (Rosner & Lane, 1986;
Matthews et al., 1981; Spencer et al., 1978), our study suffers
from the drawback that information on OC use is lacking in
detail compared to information from a case-control study
such as that of Vessey et al. (1979) or a cohort study such as
that of the Royal College of General Practitioners (1981).
The OC user group selected by Spencer et al. (1978) was
homogeneous in that all these women had used OCs at the
time of diagnosis or in the year before, but in all the studies
the range of months of use was wide. Our dichotomy at 6
months of use was pre-determined by the form in which the
data were collected but seems no more unreasonable than
supposing that only a month or two of use could possibly
affect survival. Thus our data based on 263 unselected cases
lend no support to the idea that oral contraceptives exert a
beneficial influence on growth or spread or breast tumours.
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